Imugene Stock Price To Earnings To Growth
| IMU Stock | 0.04 0 5.41% |
Imugene fundamentals help investors to digest information that contributes to Imugene's financial success or failures. It also enables traders to predict the movement of Imugene Stock. The fundamental analysis module provides a way to measure Imugene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Imugene stock.
Imugene | Price To Earnings To Growth |
Imugene Company Price To Earnings To Growth Analysis
Imugene's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Imugene has a Price To Earnings To Growth of 0.0 times. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all Australia stocks average (which is currently at 0.0).
Did you try this?
Run Latest Portfolios Now
Latest PortfoliosQuick portfolio dashboard that showcases your latest portfolios |
| All Next | Launch Module |
Imugene Fundamentals
| Return On Equity | -0.97 | ||||
| Return On Asset | -0.51 | ||||
| Operating Margin | 22.86 % | ||||
| Current Valuation | 203.56 M | ||||
| Shares Outstanding | 7.57 B | ||||
| Shares Owned By Insiders | 14.38 % | ||||
| Shares Owned By Institutions | 6.60 % | ||||
| Price To Book | 2.50 X | ||||
| Price To Sales | 59.38 X | ||||
| Revenue | 4.97 M | ||||
| Gross Profit | 11.78 M | ||||
| EBITDA | (147.98 M) | ||||
| Net Income | (149.68 M) | ||||
| Cash And Equivalents | 49.54 M | ||||
| Total Debt | 1.55 M | ||||
| Book Value Per Share | 0.02 X | ||||
| Cash Flow From Operations | (97.32 M) | ||||
| Earnings Per Share | (0.02) X | ||||
| Target Price | 0.3 | ||||
| Beta | 3.34 | ||||
| Market Capitalization | 295.12 M | ||||
| Total Asset | 151.4 M | ||||
| Retained Earnings | (289.83 M) | ||||
| Working Capital | 83.74 M | ||||
| Net Asset | 151.4 M |
About Imugene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Imugene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Imugene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Imugene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Imugene Stock Analysis
When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.